Lantheus Holdings (LNTH) : 1 brokerage houses believe that Lantheus Holdings (LNTH) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Lantheus Holdings (LNTH). Zacks Investment Research suggests a Strong Buy with a rank of 1.The median of all the 3 Wall Street Analysts endorse the stock as a Buy with a rating of 2.33.
Lantheus Holdings (LNTH) : The highest short term price target forecast on Lantheus Holdings (LNTH) is $12 and the lowest target price is $5. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $7.67 with a standard deviation of $3.79.
Also, Equity Analysts at the Brokerage Firm, Jefferies, maintains their rating on the shares of Lantheus Holdings (NASDAQ:LNTH). Jefferies has a Buy rating on the shares. As per the latest research report, the brokerage house raises the price target to $12 per share from a prior target of $8. The rating by the firm was issued on August 29, 2016.
Lantheus Holdings (NASDAQ:LNTH): After opening at $7.91, the stock dipped to an intraday low of $7.91 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.38 and the buying power remained strong till the end. The stock closed at $8.29 for the day, a gain of 3.75% for the day session. The total traded volume was 565,709. The stocks close on the previous trading day was $7.99.
Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Companys medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Companys products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Companys products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.